ARMP - Armata Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
3.9572
+0.1772 (+4.69%)
As of 11:31AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.7800
Open3.8800
Bid3.9300 x 4000
Ask3.9900 x 1000
Day's Range3.7946 - 3.9765
52 Week Range2.4500 - 6.9200
Volume7,285
Avg. Volume220,057
Market Cap43.193M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1800
Earnings DateMar 22, 2020 - Mar 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.83
  • Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
    PR Newswire

    Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently executed Securities Purchase Agreement with Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited. In connection with the closing, Armata issued 993,139 common shares and warrants to purchase 993,139 common shares in exchange for net proceeds of approximately $2.8 million. The first closing occurred following the satisfaction of certain closing conditions, including the execution of voting agreements by greater than 50.1% of the existing common stockholders of Armata in support of the $25 million private placement financing transaction. In connection with the closing, Richard Bear and Michael S. Perry, D.V.M., Ph.D., resigned from Armata's Board of Directors and two individuals designated by Innoviva, Sarah Schlesinger, M.D. and Odysseas Kostas, M.D., were appointed to fill the newly created vacancies. Armata also announced that it has withdrawn its registration statement on Form S-1 that was previously filed with the SEC.

  • Company News For Jan 29, 2020
    Zacks

    Company News For Jan 29, 2020

    Companies In The News Are: ARMP, GGG, MMM and OBCI

  • Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs
    PR Newswire

    Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that they have entered into a securities purchase agreement pursuant to which Innoviva will purchase, upon satisfaction of certain closing conditions, approximately $25 million in Armata common stock and warrant securities (excluding any consideration payable upon exercise of warrants).

  • Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
    PR Newswire

    Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

    MARINA DEL REY, Calif. , Nov. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

  • We're Keeping An Eye On Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Armata Pharmaceuticals Issues Letter to Shareholders
    PR Newswire

    Armata Pharmaceuticals Issues Letter to Shareholders

    MARINA DEL REY, Calif., Oct. 31, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the 2019 Armata Annual General Shareholders meeting to be held on December 10, 2019. It has been approximately six months since we completed the merger between C3J Therapeutics and AmpliPhi Biosciences, and I am pleased to report that the complementary capabilities and synergies that we envisioned when we brought these two companies together are being realized as anticipated.

  • Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive
    PR Newswire

    Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

    MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata's R&D spending in Australia during 2018. Armata will recognize the $1.3 million payment received in its financial statements for the quarter ending December 31, 2019. "This R&D tax rebate is an important source of non-dilutive capital that we can use to further advance development of our lead phage candidates as we prepare to initiate clinical trials next year," said Todd R. Patrick, Chief Executive Officer of Armata.

  • Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director
    PR Newswire

    Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director

    MARINA DEL REY, Calif., Oct. 16, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the appointment of Heather Dale Jones, M.D. as its first Medical Director, further strengthening Armata's clinical team as the company prepares to initiate clinical testing of its lead bacteriophage product candidates. Dr. Jones brings to the Armata team more than 20 years of experience in clinical research and medical practice.

  • Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.
    PR Newswire

    Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.

    MARINA DEL REY, Calif., Oct. 10, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has expanded its Board of Directors with the appointment of Todd C. Peterson, Ph.D. Dr. Peterson brings to the Armata Board more than 35 years of experience in biotechnology and life sciences research and development across the areas of molecular biology, nucleic acids and genomics product and technology development.

  • Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference
    PR Newswire

    Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference

    MARINA DEL REY, Calif. , Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics ...

  • Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
    PR Newswire

    Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

    MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa (also referred to herein as "Pseudomonas" or "P. aeruginosa") to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The candidate, known as AP-PA02, is being developed as a replacement for AP-PA01, which was recently featured in the peer-reviewed journal Infection following the successful treatment of a multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.

  • Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
    PR Newswire

    Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update

    MARINA DEL REY, Calif. , Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

  • How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own?
    Simply Wall St.

    How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own?

    The big shareholder groups in Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) have power over the company. Institutions...

  • Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
    PR Newswire

    Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference

    MARINA DEL REY, Calif. , Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics ...

  • Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
    PR Newswire

    Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

    MARINA DEL REY, Calif., June 18, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will host a Key Opinion Leader (KOL) meeting on phage-based therapeutics for the treatment of antimicrobial-resistant infections on June 26 from 12:00 – 1:30 PM EDT in New York City. The event will feature a presentation by Robert Schooley, MD, from the University of California-San Diego, who will discuss the rapidly growing antibiotic resistance crisis and the urgent need for the development of new antibiotic alternatives. Armata's management team will also provide an overview of the company's phage-based product candidates aimed to address areas of significant unmet clinical need by targeting key antibiotic-resistant bacteria.

  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada
    PR Newswire

    Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

    MARINA DEL REY, Calif., June 3, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company continues to strengthen its intellectual property portfolio with the allowance of two patents by the European Patent Office and one allowance by the Canadian Intellectual Property Office.

  • Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
    PR Newswire

    Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

    MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company's natural phage product, AP-PA01. The paper, entitled "Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient," appears in the peer-reviewed journal Infection.